What is claimed is:

1. A compound having the structural formula:



wherein R_1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R_2, R_3, and R_4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R_5 is hydrogen, CH_3, or CH_2OH, and R_6 is an organo group.

2. The compound of claim 1, wherein R_2 is acetate.

3. The compound of claim 1, wherein R_3 is acetate.

4. The compound of claim 1, wherein R_4 is acetate.

5. The compound of claim 1, wherein R_6 is a hydrocarbon having from 1 to 10 carbon atoms.

6. The compound of claim 1, wherein R_6 is 2-methyl-1-propene.

7. The compound of claim 1, wherein R_1 is hydrogen, methyl or ethyl.

8. The compound of claim 2, wherein R_1, R_3, R_4, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

9. The compound of claim 3, wherein R_1, R_2, R_4, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

10. The compound of claim 4, wherein R_1, R_2, R_3, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

11. A compound having the structural formula:



wherein R_1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R_2, R_3, and R_4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R_5 is hydrogen, CH_3, or CH_2OH, and R_6 is an organo group.

12. The compound of claim 11, wherein R_2 is acetate.

13. The compound of claim 11, wherein R_3 is acetate.

14. The compound of claim 11, wherein R_4 is acetate.

15. The compound of claim 11, wherein R_6 is a hydrocarbon having from 1 to 10 carbon atoms.

16. The compound of claim 11, wherein R_6 is 2-methyl-1-propene.

17. The compound of claim 11, wherein R_1 is hydrogen, methyl, or ethyl.

18. The compound of claim 12, wherein R_1, R_3, R_4, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

19. The compound of claim 13, wherein R_1, R_2, R_4, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

20. The compound of claim 14, wherein R_1, R_2, R_3, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

21. A compound of the structural formula:



wherein R_1 is a hydrogen or an alkyl or acyl residue having from 1 to 6 carbon atoms, and R_2 is an organo group.

22. The compound of claim 21, wherein R_1 is hydrogen and R_2 is 2-methyl-1-propene.

23. The compound of claim 21, wherein R_2 is a hydrocarbon having from 1 to 10 carbon atoms.

24. The compound of the structural formula:



wherein R_1 is a hydrogen or an alkyl or acyl residue having from 1 to 6 carbon atoms, and R_2 is an organo group.

25. The compound of claim 24, wherein R_1 is hydrogen and R_2 is 2-methyl-1-propene.

26. The compound of claim 24, wherein R_2 is a hydrocarbon having from 1 to 10 carbon atoms.

27. A pharmaceutical composition comprising a therapeutically effective amount of a compound having the structural formula:



wherein R_1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R_2, R_3, and R_4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R_5 is hydrogen, CH_3, or CH_2OH, and R_6 is an organo group, or a pharmaceutically acceptable salt, prodrug, or active metabolite thereof and a pharmaceutically acceptable excipient.

28. The pharmaceutical composition of claim 27, wherein R_2 is acetate.

29. The pharmaceutical composition of claim 27, wherein R_3 is acetate.

30. The pharmaceutical composition of claim 27, wherein R_4 is acetate.

31. The pharmaceutical composition of claim 27, wherein R_6 is 2-methyl-1-propene.

32. The pharmaceutical composition of claim 27, wherein R_1 is hydrogen, methyl, or ethyl.

33. The pharmaceutical composition of claim 27, wherein R_1, R_3, R_4, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

34. The pharmaceutical composition of claim 27, wherein R_1, R_2, R_4, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

35. The pharmaceutical composition of claim 27, wherein R_1, R_2, R_3, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

36. A pharmaceutical composition comprising a therapeutically effective amount of a compound having the structural formula:



wherein R_1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R_2, R_3, and R_4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R_5 is hydrogen, CH_3, or CH_2OH, and R_6 is an organo group, or a pharmaceutically acceptable salt, prodrug, or active metabolite thereof and a pharmaceutically acceptable excipient.

37. The pharmaceutical composition of claim 36, wherein R_2 is acetate.

38. The pharmaceutical composition of claim 36, wherein R_3 is acetate.

39. The pharmaceutical composition of claim 36, wherein R_4 is acetate.

40. The pharmaceutical composition of claim 36, wherein R_6 is 2-methyl-1-propene.

41. The pharmaceutical composition of claim 36, wherein R_1 is hydrogen, methyl, or ethyl.

42. The pharmaceutical composition of claim 36, wherein R_1, R_3, R_4, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

43. The pharmaceutical composition of claim 36, wherein R_1, R_2, R_4, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

44. The pharmaceutical composition of claim 36, wherein R_1, R_2, R_3, and R_5 are hydrogen, and R_6 is 2-methyl-1-propene.

45. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the structural formula:



wherein R_1 is a hydrogen or an alkyl or acyl residue having from 1 to 6 carbon atoms, and R_2 is an organo group, or a pharmaceutically acceptable salt, prodrug, or active metabolite thereof and a pharmaceutically acceptable excipient.

46. The compound of claim 45, wherein R_1 is hydrogen and R_2 is 2-methyl-1-propene.

47. A method for treating, preventing or inhibiting a disease or disorder associated with inflammation, cell-proliferation or pain in a subject comprising administering to the subject a therapeutically effective amount of a compound having the structural formula:



wherein R_1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R_2, R_3, and R_4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R_5 is hydrogen, CH_3, or CH_2OH, and R_6 is an organo group.

48. A method for treating, preventing or inhibiting a disease or disorder associated with inflammation, cell-proliferation or pain in a subject comprising administering to the subject a therapeutically effective amount of a compound having the structural formula:



wherein R_1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R_2, R_3, and R_4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R_5 is hydrogen, CH_3, or CH_2OH, and R_6 is an organo group.

49. A method for treating, preventing or inhibiting a disease or disorder associated with inflammation, cell-proliferation or pain in a subject comprising administering to the subject a therapeutically effective amount of a compound having the structural formula:



wherein R_1 is a hydrogen or an alkyl or acyl residue having from 1 to 6 carbon atoms, and R_2 is an organo group.

50. A compound having the structural formula:



, or .

51. A pharmaceutical composition comprising a therapeutically effective amount of a compound having the structural formula selected from the group consisting of:



, and , and a pharmaceutically acceptable excipient.